CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The Company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.
| Website: | www.cytosorbents.com |
| Email: | avogel@cytosorbents.com |
| Main Phone: | +1 732 329-8885 |
| Address: | 7 Deer Park Drive |
| Address 2: | Suite K |
| State: | NJ |
| City / Town: | Monmouth Junction |
| Country: | USA |
| Postal Code: | 08852 |
| Exchange: | NSC |
| CEO: | Phillip P. Chan |
| Employees: | 141 |
| NAICS: | Medical Laboratories(621511) |
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement. In this interview, Brian
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
As I write this, the Alerian MLP Index is in the midst of a five-day losing streak and broke below its year-end closing price intra-day today. The index rebounded to close back in the green for
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The Company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.
| Website: | www.cytosorbents.com |
| Email: | avogel@cytosorbents.com |
| Main Phone: | +1 732 329-8885 |
| Address: | 7 Deer Park Drive |
| Address 2: | Suite K |
| State: | NJ |
| City / Town: | Monmouth Junction |
| Country: | USA |
| Postal Code: | 08852 |
| Exchange: | NSC |
| CEO: | Phillip P. Chan |
| Employees: | 141 |
| NAICS: | Medical Laboratories(621511) |
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement. In this interview, Brian
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative
As I write this, the Alerian MLP Index is in the midst of a five-day losing streak and broke below its year-end closing price intra-day today. The index rebounded to close back in the green for
| Last Price 4.59 | Change $ 0.01 | Change % 0.22 | Tick N/A |
| Bid 4.00 | Bid Size 300.00 | Ask 5.75 | Ask Size 1,000.00 |
| Open 4.55 | High 4.66 | Low 4.53 | Prev Close 4.58 |
| Last Trade | Volume 65,778 | 52 Wk Hi 12.00 | 52 Wk Low 3.68 |
| Market Cap 148.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 32,303,231.00 | EPS (TTM) -0.53 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 26 | 55 |
| Number of Buys | 13 | 33 |
| Number of Sells | 13 | 22 |
| Net Activity | 24785 | 225628 |
| Last 10 Buys | Shares |
|---|---|
| Michael G. Bator | 1,000 |
| Eric R. Mortensen | 1,000 |
| Phillip P. Chan | 1,000 |
| Edward R. Jones | 1,000 |
| Edward R. Jones | 1,000 |
| Vincent Capponi | 1,000 |
| Phillip P. Chan | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Phillip P. Chan | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Vincent Capponi | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Vincent Capponi | 1,000 |
| Vincent Capponi | 1,000 |
| Kathleen P. Bloch | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 14 | 14 | 14 | 14 |
| Low Target Price Estimate | 11 | 11 | 11 | 11 |
| Mean Target Price Estimate | 12.6 | 12.6 | 12.6 | 12.6 |
| Standard Deviation | 1.14 | 1.14 | 1.14 | 1.14 |
| Date of Most Recent Estimate | 05/23/18 | 05/23/18 | 05/23/18 | 05/23/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-18 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-06-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-05-24 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 73 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait